TY - JOUR
T1 - Mode of death and predictors of mortality in adult Fontan survivors
T2 - A Japanese multicenter observational study
AU - On behalf of the JSACHD Fontan Investigators
AU - Ohuchi, Hideo
AU - Inai, Kei
AU - Nakamura, Makoto
AU - Park, In Sam
AU - Watanabe, Mamie
AU - Hiroshi, Ono
AU - Kim, Ki Sung
AU - Sakazaki, Hisanori
AU - Waki, Kenji
AU - Yamagishi, Hiroyuki
AU - Yamamura, Kenichiro
AU - Kuraishi, Kenji
AU - Miura, Masaru
AU - Nakai, Michikazu
AU - Nishimura, Kunihiro
AU - Niwa, Koichiro
N1 - Funding Information:
The authors thank to the all staff and participating institutions., Staffs: Kiyoshi Ogawa MD, PhD,16 Tomotaka Nakayama MD, PhD,17 Hiroshi Suzuki MD, PhD,18 Takuhiro Nishihara MD, PhD,19 Koichi Nishida MD, PhD,20 Masato Kimura MD, PhD,21 Toru Takahashi MD, PhD,22 Kentaro Omoya MD, PhD,23 Motoki Takamuro MD, PhD,24 Hiromichi Nakajima MD, PhD,25 Kenji Suda MD, PhD,26 Yuichi Nomura MD, PhD,27 Masaya Sugimoto MD, PhD,28 Fujiwara Yuko MD, PhD,29 Hitoshi Horigome MD, PhD,30 Ken Yoshimura MD, PhD,31 Hiroshi Suzuki MD, PhD,32 Manatomo Toyono, MD, PhD,33 Hidetaka Teshima, MD, PhD34., Institutions: 16 Cardiology, Saitama Children's Medical Center, Saitama, Saitama; 17 Pediatrics, Toho University, Ota-ku, Tokyo; 18 Pediatrics, Niigata University, Niigata, Niigata; 19 Pediatrics, Kumamoto Red Cross Hospital, Kumamoto, Kumamoto; 20 Pediatrics, Fukui Cardiovascular Center, Fukui, Fukui; 21 Pediatrics, Tohoku University School of Medicine, Sendai, Miyagi; 22 Pediatrics, Hirosaki University School of Medicine, Hirosaki, Aomori; 23 Pediatric Cardiology, Gifu Prefectural General Medical Center, Gifu, Gifu; 24 Cardiology, Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo, Hokkaido; 25 Cardiology, Chiba Children's Hospital, Chiba, Chiba; 26 Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka; 27 Pediatrics, Kagoshima City Hospital, Kagoshima, Kagoshima; 28 Pediatrics, Asahikawa Medical University, Asahikawa, Hokkaido; 29 Pediatrics, The JIKEI University School of Medicine, Minato-ku, Tokyo; 30 Pediatrics, Ibaraki Children's Hospital, Mito, Ibaraki; 31 Pediatrics, Kansai Medical University Hospital, Hirakata, Osaka; Pediatrics, Gunma Children's Medical Center, Shibukawa, Gunma; Pediatrics, Kosei General Hospital, Mihara, Hiroshima; Pediatrics, Engaru-Kosei General Hospital, Engaru, Hokkaido; 32 Pediatrics, Yamagata University Faculty of Medicine, Yamagata, Yamagata; 33 Pediatrics, Akita University Hospital, Akita, Akita; 34 Pediatrics, National Hospital Nagasaki Medical Center, Omura, Nagasaki; Pediatrics, Nagasaki University Hospital, Nagasaki, Nagasaki; Pediatrics, Tottori Prefectural Central Hospital, Tottori, Tottori; Pediatrics, Tsuchiya General Hospital, Hiroshima, Hiroshima; Pediatric Thoracic Surgery, Kanazawa Medical University Hospital, Kanazawa, Kanazawa., Nothing to disclose of any relationship with industry., No funding to disclose.
Publisher Copyright:
© 2018
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Background: Mortality rates may be high in adult Fontan patients; however, the clinical determinants remain unclear. Purpose: We conducted a prospective multicenter study of adult Fontan survivors to determine the 5-year mortality rate and clarify the determinants. Method and results: We followed 600 adult Fontan survivors from 40 Japanese institutions (307 men, 28 ± 7 years old, follow-up: 18 ± 6 years). The New York Heart Association (NYHA) functional class I and II was 51% and 42%, respectively. During the follow-up period of 4.1 ± 1.6 years, 33 patients died, and the 5-year survival rate was 93.5%. The mode of death was heart failure in 11 patients (34%), arrhythmia or sudden death in 8 (24%), cancer in 5 (15%), perioperative problems and hemostatic problems in 4 each (12% for each), and infection in 1 (3%). Left isomerism, prior hospitalization, protein losing enteropathy (PLE), pulmonary arteriovenous fistulae, NYHA functional class, impaired hemodynamics, hyponatremia, hepatorenal dysfunction, and use of diuretics were associated with a high mortality rate (p < 0.05–0.0001). Further, PLE (hazard ratio [HR]: 14.4), left isomerism (HR: 3.5), and NYHA (HR: 2.4) independently predicted a high 5-year high mortality (p < 0.05 for all). The incidence of cancer-related mortality increased markedly with age >40 years. Conclusions: Majority of the Japanese adult Fontan survivors had good functional status, with an acceptable 5-year survival rate. However, the significant prevalence of non-cardiac mortality highlights Fontan pathophysiology as a multi-organ disease that requires a multidisciplinary management strategy to improve the long-term outcome.
AB - Background: Mortality rates may be high in adult Fontan patients; however, the clinical determinants remain unclear. Purpose: We conducted a prospective multicenter study of adult Fontan survivors to determine the 5-year mortality rate and clarify the determinants. Method and results: We followed 600 adult Fontan survivors from 40 Japanese institutions (307 men, 28 ± 7 years old, follow-up: 18 ± 6 years). The New York Heart Association (NYHA) functional class I and II was 51% and 42%, respectively. During the follow-up period of 4.1 ± 1.6 years, 33 patients died, and the 5-year survival rate was 93.5%. The mode of death was heart failure in 11 patients (34%), arrhythmia or sudden death in 8 (24%), cancer in 5 (15%), perioperative problems and hemostatic problems in 4 each (12% for each), and infection in 1 (3%). Left isomerism, prior hospitalization, protein losing enteropathy (PLE), pulmonary arteriovenous fistulae, NYHA functional class, impaired hemodynamics, hyponatremia, hepatorenal dysfunction, and use of diuretics were associated with a high mortality rate (p < 0.05–0.0001). Further, PLE (hazard ratio [HR]: 14.4), left isomerism (HR: 3.5), and NYHA (HR: 2.4) independently predicted a high 5-year high mortality (p < 0.05 for all). The incidence of cancer-related mortality increased markedly with age >40 years. Conclusions: Majority of the Japanese adult Fontan survivors had good functional status, with an acceptable 5-year survival rate. However, the significant prevalence of non-cardiac mortality highlights Fontan pathophysiology as a multi-organ disease that requires a multidisciplinary management strategy to improve the long-term outcome.
UR - http://www.scopus.com/inward/record.url?scp=85053007062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053007062&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2018.09.002
DO - 10.1016/j.ijcard.2018.09.002
M3 - Article
C2 - 30201381
AN - SCOPUS:85053007062
SN - 0167-5273
VL - 276
SP - 74
EP - 80
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -